Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 4/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132910 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2MEN1KMT2AMGLLNLRP3 | |
| SCHEMBL10132905 | 0.93 | NLRP3 (0.35) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL6742973 | 0.93 | NLRP3 (0.35) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL6743549 | 0.89 | ALDH1A1 (0.34) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL13265148 | 0.89 | ALDH1A1 (0.34) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL6742926 | 0.88 | TDP1 (0.35) | KMT2AMGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL6742434 | 0.87 | MGLL (0.31) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL13263803 | 0.87 | MGLL (0.31) | MGLLNLRP3KDM4EALDH1A1 | |
| SCHEMBL13265318 | 0.85 | KDM4E (0.38) | MGLLKDM4EALDH1A1 | |
| SCHEMBL2473198 | 0.85 | KDM4E (0.38) | MGLLKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374788-A1 | INDANYL COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010074089-A1 | INDANYL COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | SMN1; SMN2 1932/4885MEN1 2944/4885KMT2A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.